Navigation Links
Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease
Date:1/4/2008

NEW YORK, Jan. 4 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $3.8 million for the development of a gene silencing therapeutic to treat Parkinson's disease by reducing expression of the protein alpha-synuclein. A team of researchers led by Matt Farrer, PhD, of Mayo Clinic Jacksonville (Florida) with collaborators at Alnylam Pharmaceuticals and The Parkinson's Institute and Clinical Center will work to optimize a small interfering RNA (siRNA)-based therapeutic that could slow or stop the progression of Parkinson's disease. If successful, the project could result in an entirely new class of drug targeting the alpha-synuclein gene, which has proved difficult to modulate using traditional small-molecule therapeutics.

The work is being funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 initiative. LEAPS 2007 was funded with a lead gift from the Edmond J. Safra Philanthropic Foundation. The Edmond J. Safra Philanthropic Foundation has been one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.

"Available Parkinson's treatments mask symptoms but do nothing to halt or slow underlying disease progression," said Katie Hood, chief executive officer of MJFF. "More and more scientific evidence supports the hypothesis that lowering alpha-synuclein levels in the brain could achieve the so-called 'Holy Grail' of PD research, a neuroprotective therapy. But no drugs have been identified to date that are capable of reducing alpha-synuclein expression; new approaches are needed. This LEAPS grant is characteristic of how The Michael J. Fox Foundation goes about its work -- making big bets on fresh ideas with potential to impact patients' quality of life."

While its normal function in the brain remains unknown, the accumulation of excess alpha-synuclein has been shown to be the cause of some familial forms of PD. Clinical, genetic and experiment
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 LDM Global ( http://www.ldmglobal.com ... model that is simplified and predictable with fixed fees ... As a leading international provider of legal discovery management ... has become glaringly apparent that both the courts and ... budgets and the complex pricing structure that plagues the ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... 31, 2014 Setting goals for a fitness ... on successful tips to weight loss. Fitness on the Go ... 8 years, and has worked with 6000 customers on an ... had the chance to monitor why customers start exercising with ... long they stick to their program, whether or not they ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint that ... airway to quiet snoring. , Dawn M. of Utah shared ... husband by allowing them to share the same bedroom again. ... 15 years ago and I remember nights when it was so ... to head downstairs for any relief. As the years have gone ...
(Date:7/31/2014)... York, New York (PRWEB) July 31, 2014 ... to grow, as Bernstein Liebhard LLP notes that ... that it plans to voluntarily remove its power ... to a report from Bloomberg.com, the company said ... and benefits associated with the devices remain uncertain.* ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... pills and capsules that show a tendency in the standard ... a faster and potentially unsafe manner in patients who have ... proven safe with testing in people. That,s the conclusion ... of ACS, Molecular Pharmaceutics , a bi-monthly journal. ...
... WASHINGTON, Sept. 23 In the year since the crash ... concerns despite rising unemployment levels and ongoing economic uncertainty, according to ... In a poll surveying 2,160 adults conducted by Harris Interactive(R) between ... the economy caused stress in their lives, down from 82 percent ...
... , PRINCETON, N.J., Sept. 23 Bringing a new ... makers of Trojan(R) Brand Condoms recently introduced Trojan 2GO(R), a new ... new product, which is designed to stand-up to purses, wallets, pockets ... food, drug and convenience retail locations, making Trojan 2GO both easy ...
... NORTHRIDGE, Calif., Sept. 23 Today, Nature Made(R) ... Greatness(TM) contest. Nature Made is the nation,s best-selling brand ... mass and club channels. The company celebrates the inherent greatness ... challenged Americans to submit their personal stories of greatness as ...
... cyber-bullying and an increase in violence among young women will ... Professor Kerry Carrington, head of Queensland University of Technology,s School ... confirm, contrary to general academic opinion, young women are fast ... will present her findings, to be revealed in her book ...
... Mich. Immune therapies have been explored as a way ... from the University of Michigan Comprehensive Cancer Center suggests that ... critical immune system cells. The study was done ... in the lab before being available for humans. But the ...
Cached Medicine News:Health News:Interview Alert: At Anniversary of Financial Meltdown, Psychologists Notice Downward Trends in Economic Stress 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 3Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 4Health News:National 'Greatness' Contest Winners Announced 2Health News:National 'Greatness' Contest Winners Announced 3Health News:Girls' violence on the rise 2Health News:Study looks at using the immune system to reduce prostate cancer risk 2
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... 2014 For the first time, cardiac surgeons, ... of the SynCardia temporary Total Artificial Heart in a ... on the Journal of Visualized Experiments website. ... on the SynCardia Total Artificial Heart implantation   ... of the SynCardia Total Artificial Heart," a July 18, ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... Development of Intradigm,s ICS-283, PALO ALTO, ... developer of targeted, systemic RNA interference (RNAi),therapeutics, ... company,s,TargeTran(TM) delivery system is capable of delivering ... RNAs (siRNAs) that suppress,tumor-induced angiogenesis by silencing ...
... BiPar Sciences, Inc., a,privately held biopharmaceutical ... demonstrating that BSI-401 inhibited pancreatic cancer,cell growth ... and in combination with,oxaliplatin. BSI-401 is BiPar,s ... therapies known as PARP (poly-ADP-ribose polymerase) inhibitors. ...
Cached Medicine Technology:Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2
... Tegagel hydrogel wound filler and Tegagel ... amorphous hydrogel dressings specially formulated to ... has been shown to enhance wound ... meets clinical needs for management of ...
... and Tegagel hydrogel wound filler with ... formulated to help provide a moist ... enhance wound healing. The unique, viscous, ... management of non-draining, minimally draining and ...
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
... Esteem™ External Vacuum Therapy System restores sexual ... men. Non-invasive and low cost vacuum therapy, ... desirable outcome", makes it the ideal therapy ... Therapy System causes penile rigidity that can ...
Medicine Products: